- Home
- PTPI vs TOVX Comparison
PTPI vs TOVX Comparison
Compare PTPI & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTPI
- TOVX
- Stock Information
- Founded
- PTPI 2020
- TOVX 2001
- Country
- PTPI United States
- TOVX United States
- Employees
- PTPI N/A
- TOVX 22
- Industry
- PTPI Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- PTPI Health Care
- TOVX Health Care
- Exchange
- PTPI Nasdaq
- TOVX Nasdaq
- Market Cap
- PTPI 3.1M
- TOVX 3.2M
- IPO Year
- PTPI N/A
- TOVX 2006
- Fundamental
- Price
- PTPI $0.29
- TOVX $1.14
- Analyst Decision
- PTPI
- TOVX Strong Buy
- Analyst Count
- PTPI 0
- TOVX 1
- Target Price
- PTPI N/A
- TOVX $6.00
- AVG Volume (30 Days)
- PTPI 4.4M
- TOVX 97.3K
- Earning Date
- PTPI 11-13-2024
- TOVX 11-12-2024
- Dividend Yield
- PTPI N/A
- TOVX N/A
- EPS Growth
- PTPI N/A
- TOVX N/A
- EPS
- PTPI N/A
- TOVX N/A
- Revenue
- PTPI $4,022,389.00
- TOVX N/A
- Revenue This Year
- PTPI N/A
- TOVX N/A
- Revenue Next Year
- PTPI $0.76
- TOVX N/A
- P/E Ratio
- PTPI N/A
- TOVX N/A
- Revenue Growth
- PTPI N/A
- TOVX N/A
- 52 Week Low
- PTPI $0.22
- TOVX $1.14
- 52 Week High
- PTPI $2.27
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- PTPI 46.90
- TOVX 36.15
- Support Level
- PTPI $0.26
- TOVX $1.23
- Resistance Level
- PTPI $0.59
- TOVX $1.21
- Average True Range (ATR)
- PTPI 0.07
- TOVX 0.07
- MACD
- PTPI -0.00
- TOVX 0.01
- Stochastic Oscillator
- PTPI 13.21
- TOVX 0.00
About PTPI Petros Pharmaceuticals Inc.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.